Outlook on the Psoriasis Drugs Global Market to 2025 – Players Include Pfizer, Celgene and Novartis Among Others – ResearchAndMarkets.com
December 22, 2020DUBLIN–(BUSINESS WIRE)–The “Psoriasis Drugs Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering.
The psoriasis drugs market is expected to register a CAGR of 9.3% during the forecast period.
The primary factors that are responsible for the growth of this market include the increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs.
Companies Mentioned
- Eli Lilly and Company
- Pfizer Inc.
- Johnson and Johnson (Janssen Biotech Inc.)
- Celgene Corporation
- Takeda Pharmaceutical Company Limited
- Stiefel Laboratories Inc.
- Novartis AG
- Amgen Inc. (Read more…)
- Biogen Idec
- AbbVie Inc.
Key Market Trends
Interleukin Inhibitors is Expected to Grow with a High CAGR in the Forecast Period
Interleukin inhibitors may witness the fastest growth during the forecast period, and the factors aiding these interleukin inhibitors are their improved safety and efficacy when compared to other psoriasis drugs, and their increased adoption among end users. Drugs, like Secukinumab and Ustekinumab, among others, are aiding the market growth as the usage of drugs is increasing each year.
North America Dominates the Market and is Expected to do so in the Forecast Period
North America currently dominates the market for psoriasis drugs, and it is expected to continue having a stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to the increasing prevalence of psoriasis, the presence of favorable government initiatives, the presence of developed healthcare infrastructure, high adoption of therapeutics, and the presence of key drug manufacturers. All these factors are expected to propel the market in the United States.
Key Topics Covered:
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
4.2.2 Increasing Use of Combination Therapies
4.2.3 Increase in Psoriasis Research and Pipeline Drugs
4.3 Market Restraints
4.3.1 Adverse Side Effects of Existing Medications
4.3.2 High Cost of Psoriasis Treatments
4.3.3 Extensive Drug Development and Approval Process
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Type of Treatment
5.1.1 Biologic Drugs
5.1.2 Small Molecule Systemic Drugs
5.1.3 Tropical Therapies
5.2 By Mechanism of Action
5.2.1 TNF Alpha Inhibitors
5.2.1.1 Etanercept
5.2.1.2 Certolizumab Pegol
5.2.1.3 Adalimumab
5.2.1.4 Infiximab
5.2.1.5 Golimumab
5.2.2 PDE4 Inhibitors
5.2.2.1 Apremilast
5.2.3 Interleukin Inhibitors
5.2.3.1 Secukinumab
5.2.3.2 Ustekinumab
5.2.3.3 Other Interleukin Inhibitors
5.2.4 Other Mechanisms of Action
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Parenteral
5.3.3 Topical
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/pjvhro
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900